Trade Verve Therapeutics, Inc. - VERV CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.81 |
| Open | 7.83 |
| 1-Year Change | -39.72% |
| Day's Range | 7.01 - 7.83 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 7.25 | -0.65 | -8.23% | 7.90 | 7.97 | 7.01 |
| Feb 20, 2025 | 7.81 | -0.16 | -2.01% | 7.97 | 8.01 | 7.64 |
| Feb 19, 2025 | 8.04 | -0.35 | -4.17% | 8.39 | 8.50 | 7.85 |
| Feb 18, 2025 | 8.46 | -0.12 | -1.40% | 8.58 | 9.28 | 8.29 |
| Feb 14, 2025 | 8.56 | 0.76 | 9.74% | 7.80 | 8.85 | 7.79 |
| Feb 13, 2025 | 7.68 | -0.44 | -5.42% | 8.12 | 8.14 | 7.52 |
| Feb 12, 2025 | 8.02 | 0.41 | 5.39% | 7.61 | 8.02 | 7.42 |
| Feb 11, 2025 | 7.79 | -0.06 | -0.76% | 7.85 | 7.95 | 7.61 |
| Feb 10, 2025 | 7.97 | -0.20 | -2.45% | 8.17 | 8.20 | 7.63 |
| Feb 7, 2025 | 8.13 | -0.16 | -1.93% | 8.29 | 8.47 | 8.05 |
| Feb 6, 2025 | 8.34 | -0.36 | -4.14% | 8.70 | 8.74 | 8.17 |
| Feb 5, 2025 | 8.59 | 0.42 | 5.14% | 8.17 | 8.74 | 8.12 |
| Feb 4, 2025 | 8.04 | 0.12 | 1.52% | 7.92 | 8.19 | 7.56 |
| Feb 3, 2025 | 7.50 | 0.34 | 4.75% | 7.16 | 7.55 | 6.94 |
| Jan 31, 2025 | 7.59 | 0.20 | 2.71% | 7.39 | 7.88 | 7.35 |
| Jan 30, 2025 | 7.39 | -0.44 | -5.62% | 7.83 | 7.91 | 7.36 |
| Jan 29, 2025 | 7.70 | 0.45 | 6.21% | 7.25 | 7.95 | 7.24 |
| Jan 28, 2025 | 7.23 | -0.36 | -4.74% | 7.59 | 7.59 | 6.98 |
| Jan 27, 2025 | 7.75 | -0.02 | -0.26% | 7.77 | 8.01 | 7.58 |
| Jan 24, 2025 | 7.89 | 0.00 | 0.00% | 7.89 | 8.51 | 7.79 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Verve Therapeutics, Inc. Company profile
About Verve Therapeutics Inc
Verve Therapeutics, Inc. is a genetic medicines company. The Company is engaged in pioneering a new approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. It is advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes to lower blood lipids. The Company's initial two programs focuses on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. Its pipeline of in vivo gene editing programs for atherosclerotic cardiovascular disease (ASCVD) includes VERVE-101 and ANGPTL3. The Company's lead product candidate, VERVE-101, is designed to be a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Verve Therapeutics Inc revenues was not reported. Net loss increased from $45.7M to $120.3M. Higher net loss reflects Fair Value of antidilution rights increase from $5.4M to $25.6M (expense), Fair Value Adjustment of success payment increase from $2.4M to $7.8M (expense), Interest Income - Non Bank decrease of 12% to $142K (income).
| Industry: | Biotechnology & Medical Research (NEC) |
201 Brookline Avenue
Suite 601
BOSTON
MASSACHUSETTS 02215
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com